市場調查報告書
商品編碼
1123208
呼吸系統用醫藥品的全球市場(2022年~2028年)Global Respiratory Drug Market Research and Forecast 2022-2028 |
全球呼吸系統用醫藥品的市場規模在預測期間內預計將以年複合成長率6.5%成長。慢性呼吸道疾病的流行是影響和推動市場的因素之一。此外,新產品開發的進展和小兒呼吸道疾病病例的增加也被認為是對市場增長做出重大貢獻的因素。
本報告提供全球呼吸系統用醫藥品市場相關調查分析,提供市場區隔分析,地區分析,預測,企業簡介等資訊。
Global Respiratory Drug market By Route of Administration (Oral, Injectable and Inhalable), By Application (Asthma and Chronic Obstructive Pulmonary Disease (COPD)), and By End-User (Homecare and Hospitals and Clinics) Forecast Period (2021-2027)
The global respiratory drug market is growing at a considerable CAGR of 6.5% during the forecast period. Increasing pervasiveness of chronic respiratory diseases is one of the prime factors affecting and driving the market. Increasing development of new products and increasing number of cases in children related to respiratory diseases is also estimated to be the prime factors that are contributing significantly towards the growth of the market. However, strict government rules and regulations are major factors constraints that are hindering the growth of the global respiratory drug market across the globe.
However, increasing demand for home care products is one of the key factors that are creating opportunity for the market. New product launches in the market are likely to drive the growth of the global respiratory drug market. For instance, in September 2020, Verona Pharma plc one of the companies that is clinical stage bio-pharmaceutical which emphasis on diseases related to respiratory had set forth the symptom data related to phase 2b Chronic Obstructive Pulmonary Disease (COPD). This was done in international journal of Chronic Obstructive Pulmonary Disease which highlighted the fact through this data that ensifentrine had produced improvements in functionality of lung through its all doses along with progressive betterment in symptoms related to Chronic Obstructive Pulmonary Disease.
Impact of COVID-19 on the Global Respiratory drug market
The global respiratory drug market is hardly hit by the COVID-19 pandemic since December 2019. The COVID-19 pandemic in the major economies had disrupted the manufacturing and transportation activities. However, with the lockdown restriction lifted it is likely to increase the output for respiratory drug devices for patients.
Segmental Outlook
The market is segmented based on route of administration, application and end-user. Based on route of administration, the market is segmented into oral, injectable and inhalable. By application, the market is segmented into asthma and chronic obstructive pulmonary disease (COPD). By end-user, market is segmented into homecare and hospitals and clinics.
Global Respiratory drug market Share by End- User 2020 (%)
Global Respiratory drug market Share by End- User
Based on the end-user, hospitals and clinics holds a significant share in the market. Respiratory drug along with device are mostly used and needed in the hospitals for providing proper treatment to the patient. Initially, most of the products in healthcare sector are designed for the hospitals only. Generally, the requirement of hospitals with regards to equipment related to respiratory are of two types. Firstly that can be used in emergency situations such as in ambulance and secondly it can be fixed equipment that is used in hospitals. The manufacturing company provides the equipment that are having longer life cycle with better effectiveness.
Regional Outlooks
The global respiratory drug market is analyzed based on the geographical regions that are contributing significantly towards the growth of the market. Based on the geography, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America held a considerable share in 2020 in the global respiratory drug market. Some factors that are boosting the market growth in North America are growing geriatric population, leading manufactures and players present in the region. Additionally, increasing pervasiveness of chronic respiratory diseases along with technology advancement is some other factors that are promoting the growth of the market.
Global Respiratory Drug market, by Region 2021-2027
Global Respiratory Drug market, by Region
Asia-Pacific will have Considerable Growth in the Global Respiratory Drug market
Asia-Pacific region is expected to witness significant growth opportunities for the market. Large scale population affected with asthma and chronic obstructive pulmonary disease along with increasing awareness regarding the treatment of the asthma and chronic obstructive pulmonary disease in the region are likely to drive the growth of the regional market. Further due to rising health care expenditure along with increasing R&D by market player in India, China and South Korea are also some of the factors that are affecting and impacting the growth in this market.
Market Player Outlook
Key players of the global respiratory drug market are AstraZeneca, Boehringer Ingelheim International GmbH., GlaxoSmithKline plc. Koninklijke Philips N.V., and OMRON corp., among others. To survive in the market, these players adopt different marketing strategies such as product launches, collaboration. For instance, in July 2020, Novartis AG has put forward the results from second phase IRIDIUM study. This study result indicates that one daily treatment dose which is high and medium of enerzair; breezhaler had highlighted the improvement in functionality of lung along with asthma.
In June2019, Theravance Biopharma along with Mylan N.V. had entered into agreement in order to expand the development and commercialization regards to nebulized bronchodilator in China. Revefenacin is offered with the name Yupelri that is one in a day to be used nebulized bronchodilator for which it had also got the approval in the US for Chronic Obstructive Pulmonary Disease (COPD). Moreover, now it will give effective treatment to around 100 million patients suffering from Chronic Obstructive Pulmonary Disease (COPD) in China.
The Report Covers
Market value data analysis of 2020 and forecast to 2027.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global respiratory drug market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where in the market.